Novo's trial of weight-loss drug shows improvement in fatty liver disease

By Sriparna Roy (Reuters) -Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty liver disease by reducing scarring of the organ without worsening the condition. The study used 2.4 milligram dose of semaglutide to treat a liver condition called metabolic dysfunction-associated steatohepatitis, or MASH, in one part of the trial